The Pathophysiology of Inhalational Brucellosis in Balb/c Mice by Henning, Lisa N. et al.
The Pathophysiology of Inhalational
Brucellosis in Balb/c Mice
Lisa N. Henning, Karen T. Gillum, David A. Fisher, Roy E. Barnewall, Robert T. Krile, Michael S. Anderson,
Michael J. Ryan & Richard L. Warren
Battelle 505 King Avenue Columbus, Ohio 43201.
To characterize the clinical presentation and pathophysiology of inhalational brucellosis, Balb/c mice were
challenged with Brucella melitensis 16M in a nose-only aerosol exposure chamber. A low dose of 1000
cfu/animal of B. melitensis resulted in 45% of mice with tissue burdens eight weeks post-challenge. The
naturalhistoryofbrucellosisinmicechallengedbyhigheraerosoldoseswasexaminedbyserialeuthanizing
mice over an eight week period. Higher challenge doses of 1.00E105 and 5.00E105 cfu resulted in positive
blood cultures 14 days post-challenge and bacterial burdens were observed in the lung, liver and/or spleens
14 days post-challenge. In addition, the progression of brucellosis was similar between mice challenged by
theintranasalandaerosolroutes.TheresultsfromthisstudysupporttheuseoftheBalb/caerosolnose-only
brucellosis mouse model for the evaluation of therapeutics against inhalational brucellosis.
S
Brucella species are Gram negative coccobacilli that can cause significant disease in humans and animals.
Brucella melitensis, one of the major Brucella species that cause disease in humans and animals, is an
etiologicagentforbrucellosis.Humansarecommonlyinfectedfollowingcontactwithinfectedanimalsand
the ingestion of contaminated milk, milk products and meat. Brucellosis is one of the most common laboratory
acquired infections, as well as the most common zoonosis
1,2. While humans can be asymptomatic for weeks,
months or years following infection, the typical symptoms associated with brucellosis include flu-like symptoms
such as fever, night sweats, headache, depression and arthritis. Meningitis and endocarditis, although not
common, are associated with chronic brucellosis. Brucellosis is usually not fatal (less than 5%), but most bru-
cellosis-relateddeathsoccurforpatientswithendocarditis
3.Inaddition,despiteappropriateantibiotictreatment,
relapses can occur
4–9. The relapse rate following antibiotic therapy depends upon the types of antibiotic used, the
duration of treatment, and patient population
5,9–14.
Brucella species are considered potential biological warfare agents due to high infectivity, ease of aerosol
infection, ability to incapacitate infected people and the persistent nature of human disease
13. Therefore, an
appropriate small animal model is needed to evaluate the efficacy of novel vaccines and therapeutics against
brucellosis.
Intraperitoneal (IP), intranasal (IN),or whole-body aerosolroutes of challenge
15–18have beenusedto establish
brucellosis in mice. For each of these routes of exposure, Brucella rapidly spread from the site of challenge to
regional lymph nodes, then to the liver and spleen.
We have developed a nose-only aerosol exposure model to test the efficacy of antibiotics and vaccines
against inhalational brucellosis under the Food and Drug Administration (FDA) ‘‘Animal Rule.’’ In contrast
to whole-body exposure systems as previously described, the Balb/c the nose-only aerosol challenge system
reduces infection of the oral mucosa from animals licking contaminated fur. This study characterized the
nose-only chronic Balb/c inhalational brucellosis model over an eight-week time period in which seven
aerosol challenge doses were examined to determine the optimal dose for future treatment efficacy studies.
An IN challenge group was also included in this study to bridge our results with a previously published IN
challenge study
15.
The clinical presentation and pathophysiology of inhalational and IN brucellosis in mice were examined by
measuring body temperature, clinical hematology, blood culture, tissue burden and splenomegaly during the
progressionofdisease.Grossnecropsieswereperformedatthescheduledeuthanasiatimepointsandtissueswere
collected and evaluated by a board-certified veterinary pathologist for microscopic lesions. This study provided
datathatfurtherexpandstheBalb/cmousemodelforchronicinhalationalbrucellosisandsupportstheuseofthe
nose-only aerosol model for testing novel vaccine and therapeutics for the treatment of brucellosis.
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Characterization of the Nose-Only Aerosol Exposure System. The
relationship between the calculated aerosol concentration and the
targetnebulizerconcentrationwascharacterizedbythemodelwitha
resulting slope of .0.99. The mean spray factor for each aerosol
dissemination is shown in Table 1. The mean spray factor for all
12 aerosol disseminations was 1.53E-06 (95% confidence interval
8.68E-7, 2.68E-6).
Therelationshipbetweencalculatedaerosolconcentrationandthe
target nebulizer concentration indicates that the log10 aerosol con-
centration increases approximately 0.9921 log10 for each 1.0 log10
increase in nebulizer concentration (cfu/mL). The 95% confidence
interval for the slope is (0.9746, 1.0095), which is significantly dif-
ferent from zero (p 5 , 0.0001). This model relationship between
aerosolconcentrationandtargetnebulizerconcentrationisshownin
Figure 1.
Low dose aerosol challenge study. In the low dose study, mice
r e c e i v e da na e r o s o lc h a l l e n g ed o s eo f2 . 3 0 E 101 cfu (target of
3.00E101 cfu), 7.40E101 cfu (target of 1.00E102 cfu), 2.63E1
02 cfu (target of 3.00E102 cfu) or 9.48E102 cfu (target of
1.00E103 cfu) B. melitensis (Table 2). The MMAD of B. melitensis
was 3.41 mm, which is consistent with a particle size that will deposit
within the lower respiratory tract
19. Mice were euthanized eight weeks
post-challenge, and the bacterial burden in the blood, lung, liver and
spleen were determined for each mouse by qualitative (blood) or
quantitative (tissue) plate count. The low-dose exposure of 30 cfu
resulted in bacteria only being recovered from the lung, liver or
spleen of one mouse, and there were no bacteria detected from the
tissues of mice exposed to 100 cfu B. melitensis. A targeted challenge
dose of 300 cfu resulted in a limited number of bacteria being
recovered from the lung, liver and spleen in 2/20, 0/20 and 3/20,
respectively, while the highest challenge dose of 1000 cfu resulted in
45% (9/20) of the mice having detectable levels of bacteria in the
spleen (8/9 below limit of quantification). None of the mice
challenged in the low-dose aerosol study were bacteremic by blood
culture (data not shown).
Kinetics of the pathophysiology of inhalational brucellosis study. In
ordertoachieveahigherinfectionrate,thetargetedaerosoldosewas
increased for the kinetics of pathophysiology study. Mice were chal-
lengedwithanaerosoldoseof2.26E104 cfuto2.28E104 cfu(target
of1.0E104 cfu;Groups6–9),2.15E105 cfuto2.38E105 cfu(target
of 1.0E105 cfu; Groups 10–13) or 8.73E105 cfu to 1.12E106 cfu
(targetof5.00E105 cfu;Groups14–17)B.melitensis16 M(Table2).
In these aerosol challenges, the MMAD of B. melitensis was 2.96 mm,
which is consistent with a particle size that will deposit within the
lower respiratory tract. Mice were serially euthanized at 14, 28, 42
and 56 days post-challenge. The kinetics of inhalational brucellosis
was followed by enriched blood culture and quantitative plate count
Table 1 | Geometric Mean for Aerosol Concentration and Spray Factor for Each Test Day
Aerosol Concentration (cfu/L) Spray Factor
Target Nebulizer
Concentration
(cfu/mL)
Geometric
Mean
(11/16)
Geometric
Mean
(11/17)
Geometric
Mean
(11/18)
Geometric Mean
Across Three
Test Days
Geometric
Mean
(11/16)
Geometric
Mean
(11/17)
Geometric
Mean
(11/18)
Geometric Mean
Across Three
Test Days
1.03 10
5 1.423 10
2 1.943 10
2 1.633 10
2 1.653 10
2 1.423 10
26 1.943 10
26 1.633 10
26 1.653 10
26
1.03 10
6 1.213 10
3 1.943 10
3 1.283 10
3 1.443 10
3 1.213 10
26 1.943 10
26 1.283 10
26 1.443 10
26
1.03 10
7 1.283 10
4 1.953 10
4 1.313 10
4 1.483 10
4 1.283 10
26 1.953 10
26 1.313 10
26 1.483 10
26
1.03 10
8 1.343 10
5 2.093 10
5 1.303 10
5 1.543 10
5 1.343 10
26 2.093 10
26 1.303 10
26 1.543 10
26
All Data N/A N/A N/A 1.543 10
5 1.313 10
26 1.983 10
26 1.373 10
26 1.533 10
26
N/A 5 Not applicable.
Figure 1 | Relationship between aerosol concentration and target nebulizer concentration. The enumerated aerosol concentration was plotted against
thetargetednebulizerconcentrationsforallthreesprayfactortestdays.Bluesquare5Day1;redcircle5Day2;Greentriangle5Day3;Themeanspray
factor for all 12 aerosol disseminations was 1.53E-06 (95% CI 5 8.68E-07, 2.68E-6).
www.nature.com/scientificreports
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disease was characterized. Samples of blood were analyzed for
changes in blood hematology parameters.
Clinical observations and body temperature. None of the aerosol-
challenged mice showed overt signs of infection due to brucellosis
(i.e.hunchedposture,ruffledfur).Inaddition,therewerenochanges
in core body temperature associated with brucellosis infection. The
lack of fever is consistent with the lack of physical signs observed in
the Balb/c mice in this study.
Hematology. Overall, there were minimal changes in the he-
matology parameters for all the aerosol challenged Balb/c mice,
which is similar to observations for the non-human primate
(NHP) inhalational brucellosis model
20 and human brucellosis
patients
4,20. Mild leucopenia with relative lymphocytosis, along
with mild anemia and thrombocytopenia has been observed in
human brucellosis patients
21. In this study, trends in red blood
cell parameters of challenged animals compared to unchallenged
controls included mild decreases in red blood cells, hemoglobin,
hematocrit, mean corpuscular volume (MCV) and slight increases
in red cell distribution width (RDW) and corpuscular hemoglobin
concentration mean (CHCM) (data not shown). While the group
mean values were not severe enough to classify as anemia, these
trends correlate to the mild anemia observed in humans
4.
Splenomegaly.Spleenweightsweremeasuredforeachanimalonthe
day of scheduled euthanasia. As shown in Figure 2, on Day 14 post-
challenge, there was a statistically significant difference (T-Test) in
the spleen size of animals aerosol challenged with 1.00E105 (p ,
0.05) or 5.00E105 cfu (p , 0.001) or with 1.00E104 cfu (p , 0.05)
by IN compared to control. By Day 28, splenomegaly was observed
for all three aerosol challenge dose groups and the IN challenge dose
group (statistically significant compared to control for all groups).
The enlarged spleen size appears to peak on Day 42 post-challenge
for the two lower aerosol-challenge doses and the IN dose, while the
aerosol challenge with 5.0 x 10
5 cfu appears to result in a linear
increase in splenomegaly compared to unchallenged spleens. The
kinetics of splenomegaly were similar in mice challenged with
1.0E104 cfu B. melitensis by either the aerosol or IN route.
Blood culture. Blood samples were enriched prior to plating to
improve the probability of detecting low levels of bacteria in whole
blood samples. As shown in Table 3, mice challenged with
1.0E104 cfu were negative for B. melitensis cultures until Day 42
post-challenge.AtDay14post-challenge,17%(2/12)and42%(5/12)
of animals aerosol challenged with 1.0E105 cfu and 5.0E105 cfu,
respectively, yielded positive blood cultures. Positive blood cultures
peaked on Day 42 post-challenge for all three aerosol-challenge dose
groups and the IN challenge group. The kinetics of positive blood
cultures was similar in mice challenged with 1.0E104 cfu by the
aerosol or IN route.
There were significantly more mice in the highest aerosol-chal-
lenge group (5.0E105 cfu) with positive blood cultures on Day 14
post-challenge than mice given an aerosol challenge of 1.0E104 cfu.
In addition, there were a significantly greater number of positive
blood cultures for all of the groups of challenged mice compared
to the unchallenged group on Day 42 and a significant difference
between the highest aerosol-challenge group and the unchallenged
group on Days 28 and 56. There were no statistically significant
Table 2 | Summary of Challenge Data
Group Number of Mice
Day of Scheduled Euthanasia
(post-challenge)
Target challenge dosage
(cfu/mouse)
Calculated inhaled
dosage (cfu)
Aerosol
a
Low Dose
Aerosol
Challenge Study
1 20 Day 54 3.00E101 2.30E101
2 20 Day 54 1.00E102 7.40E101
3 20 Day 55 3.00E102 2.63E102
4 20 Day 56 1.00E103 9.48E102
5 20 Day 56 0.00E100 0.00E100
Kinetics of
Pathophysiology
Study
6 11 Day 14 1.00E104 2.26E104
7 11 Day 28 1.00E104 2.26E104
8 11 Day 42 1.00E104 2.28E104
9 12 Day 56 1.00E104 2.28E104
10 12 Day 14 1.00E105 2.15E105
11 12 Day 28 1.00E105 2.15E105
12 11 Day 42 1.00E105 2.38E105
13 11 Day 56 1.00E105 2.38E105
14 12 Day 14 5.00E105 8.73E105
15 11 Day 28 5.00E105 8.73E105
16 12 Day 42 5.00E105 1.12E106
17 12 Day 56 5.00E105 1.12E106
18 12 Day 56 0.00E100 0.00E100
Intranasal
19 12 Day 14 1.00E104
20 12 Day 21 1.00E104
21 12 Day 42 1.00E104
22 12 Day 56 1.00E104
aCalculated based on estimated concentration of B. melitensis 16 M in the exposure chamber and the total volume of air inhaled by the mice.
Theaerosolconcentration(cfu/L)wascalculatedasfollows:AC5(C3V)/(S3T),whereAC5AerosolConcentration(cfu/L),C5AGIconcentration(cfu/mL),V5AGIsamplervolume(mL),S5sampling
rate (,6 L/min), and T 5 Exposure time (min).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 495 | DOI: 10.1038/srep00495 3Figure 2 | The kinetics of spleen size in Balb/c mice challenged with aerosol doses of 1.00E104 cfu (A), 1.00E105 cfu (B) or 5.00E105 cfu (C), or an
intranasaldoseof1.00E104 cfu(D)B.melitensis. Averagespleensizeswithstandarderrorofthemeanareillustratedateachscheduledeuthanasiatime
point. The average unchallenged control spleen sizes are included on Day 0 in A, B, C, and D for comparison to the challenged animals. * 5 p , 0.05
compared to control; ** 5 p , 0.001 compared to control.
Table 3 | Enriched Blood Culture Results
Group Route of Challenge Target dose (cfu/mouse) Blood Culture Collection
Number of animals positive/Total
number of animals in group
6 Aerosol 1.00E104 Day 14 0/11
7 Aerosol 1.00E104 Day 28 0/11
8 Aerosol 1.00E104 Day 42 6/11*
9 Aerosol 1.00E104 Day 56 4/12
10 Aerosol 1.00E105 Day 14 2/12
11 Aerosol 1.00E105 Day 28 2/12
12 Aerosol 1.00E105 Day 42 6/11
13 Aerosol 1.00E105 Day 56 4/11
14 Aerosol 5.00E105 Day 14 5/12**
15 Aerosol 5.00E105 Day 28 7/11*
16 Aerosol 5.00E105 Day 42 10/12*
17 Aerosol 5.00E105 Day 56 7/12*
18 N/A N/A Day 56 0/12
19 Intranasal 1.00E104 Day 14 1/12
20 Intranasal 1.00E104 Day 28 2/12
21 Intranasal 1.00E104 Day 42 5/12*
22 Intranasal 1.00E104 Day 56 2/12
N/A 5 not applicable.
*5 Significantly greater than the number of positive blood cultures obtained from unchallenged mice.
**Significantly greater than the number of positive cultures obtained from unchallenged mice and mice challenged with 1.00 E104 cfu on Day 14; Fisher’s exact test p , 0.05.
www.nature.com/scientificreports
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between any of the challenge groups on Days 42 and 56 post-
challenge (Table 3).
Tissue burden. Bacterial burden was detected earlier than positive
blood cultures for the lowest aerosol challenge group [lung (3/6),
liver (2/6), and/or spleen (6/6)14 days post-challenge]. Notably, a
bacterialburdeninthelung (15/18),liver(12/18),and/orspleen(17/
18) was detected for animals aerosol challenged with 1.0E104 cfu,
1.0E105 cfu, or 5.0E105 cfu B. melitensis. There was a trend of an
increasing percentage of animals with a bacterial burden in each
tissue with increasing challenge dose (and a higher bacterial
burden). In addition, the spleen tended to have higher bacterial
counts at all time points than the liver or lungs for all three
challenge doses (Figure 3). Mice challenged with 1.0E104 cfu by
the aerosol or IN route had similar spleen, lung and liver bacterial
burden kinetics. Similar to the aerosol challenge, the IN challenge
resultedinabacterialburdeninlungsandliverthatpeakedat28days
post-challenge; the tissue burden in the spleen peaked at 42 days
post-challenge.
Pathology. Splenomegaly was the only gross finding that was
observed for animals in the pathophysiology study. On Day 56
post-challenge, 25% (3/12), 9% (1/11) and 25% (3/12) of animals
Figure 3 | Tissue burden in animals challenged with B. melitensis 16 M. Bacterial burden was measured from the spleen (A, B, C, J), lung (D, E, F,K)
and liver (G,H,I,L) from animals aerosol challenged with 1.00E104 cfu (A,D,G), 1.00E105 cfu (B,E,H) or 5.00E105 cfu (C,F,I), or administered an
intranasal dose of 1.00E104 cfu (J,K,L) B. melitensis. Individual animal results are displayed.
www.nature.com/scientificreports
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and 5.0E105 cfu B. melitensis, respectively, were observed with
enlarged spleens. Splenomegaly was also noted for one animal on
Day 14 post-challenge for the 5.0E105 cfu challenge group.
Table 4 shows the incidence of Brucella-related microscopic
lesions, with average severity scores for animals by group. Mi-
croscopic lesions observed in the enlarged spleens were consistent
with B. melitensis-induced splenic granulomatous inflammation
[43% (9/21), 73% (16/22), 74% (17/23), and 50% (12/24) for aerosol
doses1.00E104,1.00E105, 5.00E105,and 1.00E104(IN), respect-
ively] and/or increased extramedullary hematopoiesis [62% (13/21),
59% (13/22), 70% (16/23), and 38% (9/24) for aerosol doses
1.00E104, 1.00E105, 5.00E105, and 1.00E104 (IN), respectively].
No microscopic lesions were noted in the one enlarged spleen from
themousegivenanIN challenge.Spleens fromunchallenged control
animals had normal histology.
In addition to the microscopic lesions in the spleen, prominent
microscopic lesions were observed in other tissues in challenged
mice. Chronic epicardial inflammation was characterized by accu-
mulations of mononuclear cells and lymphocytes on the heart sur-
face and was mostly in or near the base of the heart rather than the
apex [5% (1/21), 14% (3/22), 26% (6/23), and 17% (4/24) for aerosol
doses1.00E104,1.00E105, 5.00E105,and 1.00E104(IN), respect-
ively]. Perivascular or peribronchiolar mononuclear cell infiltration
[0% (0/21), 14% (3/22), 17% (4/23), and 4% (1/24) for aerosol doses
1.00E104, 1.00E105, 5.00E105, and 1.00E104 (IN), respectively]
and chronic inflammation of the pleura or mediastinum [52% (11/
21), 41% (9/22), 65% (15/23), and 33% (8/24) for aerosol doses
1.00E104, 1.00E105, 5.00E105, and 1.00E104 (IN), respectively]
was observed in the lungs. Plasma cell hyperplasia [30% (6/20), 25%
(4/16), 50% (10/20), and 14% (3/21) for aerosol doses 1.00E104,
1.00E105,5.00E105, and1.00E104(IN),respectively] andinfiltra-
tion of sinuses by mononuclear cells [23% (5/21), 18% (4/22), 35%
(8/23), and 4% (1/24) for aerosol doses 1.00E104, 1.00E105,
5.00E105,and1.00E104(IN),respectively]werenotedinthemedi-
astinal lymph nodes. Similar lesions were observed in the liver and
spleen, including the granulomatous inflammation and increased
extramedullary hematopoiesis. A few animals [19% (4/21), 27% (6/
22), 13% (3/23), and 0% (0/24) for aerosol doses 1.00E104,
1.00E105, 5.00E105, and 1.00E104 (IN), respectively] had chronic
inflammation in the kidneys, which was characterized by infiltration
of mononuclear and polymorphonuclear inflammatory cells in
the interstitial tissue of the kidney and nearby tubules or the renal
pelvis.
Pathology results were similar regardless of the route of admin-
istration(aerosolorIN),orchallengedose.However,theincidenceof
chronicepicardialinflammation,chronicinflammationofthepleura
or mediastinum, mediastinal lymph node plasma cell hyperplasia
and splenic increased extramedullary hematopoiesis were highest
in animals aerosol-challenged with 5.0 x 10
5 cfu B. melitensis.
Discussion
These studies present a small animal model for inhalational brucel-
losis by characterizing the spray factor for the nose-only multi-
animal exposure system and then assessing the pathophysiology of
inhalational brucellosis in Balb/c mice. In the spray factor study, the
aerosolconcentrationwasfoundtobenearlydirectlyproportionalto
the targeted nebulizer concentration (statistically significant linear
relationship), indicating the spray factor is a nearly constant value.
The mouse nose-only aerosol system was characterized for brucel-
losisstudiesasaresult oftheconsistent dataobtained fromthespray
factor study and this aerosol system was subsequently used for
Brucella mouse studies.
The optimal challenge dose to be used to examine the patho-
physiologyofinhalationalbrucellosisoveraneight-weektimeperiod
was determined based on the infection rate (tissue burden) in the
low-dose aerosol study. Since only 45% of mice challenged with the
aerosol dose of 1.00E103 cfu had a bacterial tissue burden, it was
concluded thatamuch higherdose should beusedin thesubsequent
pathophysiology study to infect at least 95% of the challenged ani-
mals.Enrichmentofbloodsampleswasperformedpriortoplatingto
Table 4 | Incidence Summary of Brucella-related Microscopic Observations with Average Severity
Tissue/
Observation
Number
examined
a
(1.00E104
cfu; aerosol)
Number
observed
Average
Severity
Number
examined
a
(1.00E105
cfu; aerosol)
Number
observed
Average
Severity
Number
examined
a
(5.00E105
cfu; aerosol)
Number
observed
Average
Severity
Number
examined
a
(1.00E104
cfu;
intranasal)
Number
observed
Average
Severity
Liver: Inflammation 21 16 1.0 22 16 1.0 23 21 1.2 24 18 0.7
Hematopoiesis 21 5 0.3 22 5 0.3 23 2 0.1 24 2 0.1
Infiltration of
mononuclear cells
21 2 0.1 22 0 0.0 23 0 0.0 24 0 0.0
Lung: Inflammation 21 11 0.5 22 9 0.4 23 15 0.7 24 8 0.4
Mediastinal Lymph
node: Infiltration
of mononuclear
cells, sinus
20 5 0.3 16 4 0.3 20 8 0.7 21 1 0.0
Hyperplasia,
plasma cells
20 6 0.4 16 4 0.2 20 10 0.6 21 3 0.0
Spleen:
Granulomatous
inflammation
21 9 0.6 22 16 1.0 23 17 1.1 24 12 0.7
Increased
extramedullary
hematopoeisis
21 13 0.6 22 13 0.8 23 16 0.9 24 9 0.4
Heart: Epicardial
inflammation
21 1 0.1 22 3 0.2 23 6 0.3 24 4 0.2
Kidney:
Inflammation
21 4 0.2 22 6 0.3 23 3 0.2 24 0 0.0
Lesions were graded on a scale of 1-4: 1, Minimal 5 least detectable lesion; 2, Mild, 5 Easily discemable lesion; 3, Moderate 5 Change affecting large area of represented tissues with potential to be
relevant; 4, Marked 5 lesion that approached maximal.
www.nature.com/scientificreports
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that positive results can vary when blood is directly plated
20.
The kinetics of brucellosis showed modest changes in hematol-
ogy parameters during the eight-week post-challenge period. The
lack of physical changes and unremarkable hematology results for
the aerosol and IN challenged mice is consistent with human bru-
cellosis patients, in which constitutive symptoms were observed in
only 26% of 100 studied human brucellosis cases, and hematology
results were indistinct for the majority of these patients
2,21–25.I n
addition, the mouse model is consistent with the NHP inhalational
brucellosis model
20,26, in which abnormal clinical observations were
rarely noted and the clinical hematology results only involved
minimal changes to anemia-related parameters
20. Endocarditis
was observed for 8% (14/186) of challenged mice, which is con-
sistent with this rare complication being observed in human bru-
cellosis patients
24.
While the inhalational brucellosis mouse model appears consist-
entwith human patientsandother animal models inregards tonon-
specific clinical parameters, the mouse model does differ in regards
to the effect of the infection on body temperature. Unlike the vast
majority of human brucellosis patients and the NHP inhalational
brucellosis model, the aerosol- and IN-challenged mice did not
exhibit a fever at any point during the post-challenge period
20,21.
The lack of a fever in mice infected with brucellosis has been noted
previously by Silva et al.
18.
Despitetheabsenceofovertclinicalsignsinchallengedmice,these
animals were infected with brucellosis as shown by detection of
bacteria in the blood, lung, liver, and spleen in the pathophysiology
study.Similartohumandisease,positivebloodcultureswerevariable
as 22% (10/45), 30% (14/46) and 62% (29/47) of mice challenged
with a Brucella aerosol dose of 1.0 x 10
4 cfu, 1.0 x 10
5 cfu, or 5.0 x
10
5 cfu B. melitensis, respectively, had positive cultures
27. Therefore,
a higher exposure dose of B. melitensis appears to increase the prob-
ability of detecting these bacteria in a blood sample. Notably, these
positive cultures were observed after blood samples were enriched
priortoplatingonMTMagar.Inaddition,micechallengedbytheIN
route had a similar percentage of positive cultures (21%; 10/48)
compared to the corresponding aerosol challenge dose group of
1.00E104 cfu.
While blood samples were enriched to increase the probability of
detecting positive cultures, bacterial burdens were readily identified
insamplesfollowingdirectplatingonMTMagar.Abacterialburden
was detected for 93% (67/72) and 96% (23/24) of aerosol and IN
challenged animals, respectively, in the lung, liver and/or spleen at
the scheduled euthanasia time points, indicating nearly all animals
were infected with B. melitensis. In addition, the largest B. melitensis
burdens were typically observed in the spleen (all three challenge
doses),whichisconsistentwiththeNHPbrucellosismodelandother
mouse brucellosis models (IP and aerosol whole body challenge
routes)
16,17,20,26. Although the spleen appears to be the primary target
of Brucella in aerosol infection with B. melitensis 16 M in Balb/c
mice, the recovery of Brucella from the lung and liver in this study
was more variable and with lower burdens than the other published
aerosol and IN challenges
15,17,28,29. This difference could be due to
differences in the aerosol system and the method used to determine
the exposure dose, to normal variation in the infection rate and
dissemination in the tissues, or to bacterial strain differences. In
addition to the clinical parameters assessed, tissues from the animals
notevaluatedfortissueburdenwereassessed formicroscopiclesions
inordertodefinethepathologyofB.melitensis-infectedmiceduring
theeight-weektimeperiod.Consistentwithhumandiseaseandother
brucellosisanimalmodels(NHP,mouse),microscopiclesionsassoc-
iated with the lungs, lymph nodes, liver, kidney, and spleen were
observed. In addition, endocarditis was observed for 8% (14/186)
of challenged mice, and this infrequent observation has been noted
for some human brucellosis patients
24.
The results from this study suggest that this small animal model
can be used to assess efficacy of vaccines, post-exposure prophylac-
ticsandtherapeuticsbymonitoringsplenomegaly,bloodcultureand
bacterialburdeninthelung,liverandspleenoftreatedanduntreated
animals. In addition, the data from this study suggest that an appro-
priatetimetoadministeratherapeutictoaBalb/cmouseafteraerosol
or IN exposure to B. melitensis is two weeks post-challenge, based
uponthevastmajorityofanimals(78%)exhibitingabacterialburden
by this time point.
In summary, the BALB/c mouse aerosol model of brucellosis was
developed that can be used to test the efficacy of antibiotic treatment
regimens under the FDA Animal Rule. A clinically relevant end-
point in this model would be assessment of bacterial burden in the
spleen, liver, and lung of treated and untreated animals.
Methods
Brucella melitensis 16 M strain and preparation for aerosol challenge. Brucella
melitensis 16 M biovar 1 ATCC 23456 was obtained from American Type Culture
Collection (ATCC; Manassas, VA; original preparation, 1998). B. melitensis was
prepared for aerosol challenge as previously described
20.
Characterization of the nose-only aerosol exposure system for inhalational
brucellosis. The aerosol exposure system used for characterization testing consisted
of a nose-only exposure tower (CH Technologies, Inc., Westwood, NJ), which
provides the ability to simultaneously challenge up to 30 mice. Aerosols were
performed as previously described
30. The Mass Median Aerodynamic Diameter
(MMAD) of the aerosol was determined for at least one time point during each 10-
minute test with an Aerodynamic Particle SizerH Spectrometer (APS Model 3321
TSI, Inc., Shoreview, MN).
FourdifferenttargetedstartingconcentrationsofB.melitensis(1.0E105,1.0E106,
1.0E107, and 1.0E108 cfu/mL) were aerosolized for 10 minutes in triplicate and
repeated over three days. A six-jet Collison nebulizer (BGI, Waltham, MA) with a
precious fluid jar was used to generate a controlled delivery of aerosolized B. meli-
tensis 16 M from a liquid suspension at the target starting concentrations into the
exposure chamber (11 cm x 8 cm). Side-by-side aerosol samples were collected from
the exposure chamber using glass impingers (model 7541 Ace Glass, Inc) to examine
for spatial uniformity of the aerosol. The impinger contained approximately 20 6
2 mL of Heart Infusion Broth (HIB) and anti-foam A, and was kept on ice during
aerosol sampling. The impinger samples were serially diluted10-fold, and 0.1 mL
samples of each dilution plated on tryptic soy agar plates containing 5% sheep blood.
After 48–96 hincubationat 37uC the numberof colonies oneach plate werecounted
and results expressed as colony forming units per mL (cfu/mL). The temperature,
relative humidity, and aerosol particle size were monitored for at least one time point
during each 10-minute test at approximately 5 minutes into each test.
Animals. Balb/c mice (50% female, 50% male; Charles River Laboratories
International, Inc., Wilmington, MA) were 6–8 weeks old at the time of receipt and
weighed at least 16 g. For the clinical presentation and pathophysiology study, mice
were implanted with a programmable temperature transponder chip (IPTT-300,
BMDS, Seaford, DE) injected subcutaneously prior to challenge. Animals were
anesthetized with xylazine (10–12 mg/kg IP) and ketamine (80–100 mg/kg IP) prior
to injection of the temperature probe. All animals were in good health, free of
malformations and exhibited no signs of clinical disease. The animal protocols were
approved by Battelle’s Institute Animal Care and Use Committee (IACUC) and the
Department of Defense Animal Care and Use Review Office (ACURO) prior to the
start of a study.
PreparationforINchallenge.FreshB.melitensis16 Msuspensionswerepreparedas
previously described
20. The dosing material was diluted to a concentration of
3.33E105 cfu B. melitensis/mL to reach target doses of 1.0E104 cfu/animal. One
milliliter of the challenge material was prepared for each group.
Aerosol challenge. The aerosol challenge was performed as described above, except
for a single impinger was utilized to sample for viable organisms in the aerosol. Mice
were exposed to the challenge dose for 10 minutes. In the low dose aerosol study, 20
mice(50%female,50%male)wereexposedtoachievetargeteddosesof30(Group1),
100 (Group 2), 300 (Group 3) or 1000 (Group 4) cfu B. melitensis. To follow the
kinetics of pathophysiology brucellosis, mice were serially euthanized following
aerosol challenge. Twelve groups of 11 to 12 mice each were challenged via aerosol
exposure on one study day, and one group of 12 mice were used as unchallenged
controls (Group 18).
INchallenge.Fourgroupsof12miceeach(Groups19–22)werechallengedbytheIN
route. Mice were anesthetized IP with xylazine (10–12 mg/kg) and ketamine
(80–100 mg/kg). A 30mL volume containing 1.00E104 B. melitensis cfu was
administered with a micropipette dropwise into the external nares of each mouse.
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were measured for 2.5 days prior to challenge (aerosol exposure) or 9.5 days prior to
challenge (IN exposure). Temperatures were measured twice daily via the
temperature chip following challenge.
In the low dose aerosol study, mice were euthanized eight weeks after challenge.In
the pathophysiology study, mice were serially euthanized, according to Table 1. On
the scheduled euthanasia day, mice were anesthetized with IP ketamine (99 mg/kg)
and xylazine (11 mg/kg), and a terminal blood draw was performed by cardiac
puncture into EDTA tubes for hematology (pathophysiology study) and blood cul-
ture analysis (low dose aerosol study and pathophysiology study). Hematology
(Siemens Advia 120 hematology analyzer) included white blood cell count (WBC),
differential leukocyte (% and absolute) count, neutrophil/lymphocyte ratio (N/L
ratio), hemoglobin (HGB), hematocrit (HCT), red blood cell count (RBC), mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpus-
cular hemoglobin concentration (MCHC), corpuscular hemoglobin concentration
mean (CHCM), red cell distribution width (RDW), platelet count (PLT) and mean
platelet volume (MPV).
Whole blood from EDTA tubes was qualitatively tested for bacteremia by
culture by direct plating (low dose aerosol study) or enriched (pathophysiology
study) methods. For the enrichment method, approximately 30–40 mL of each
blood sample was placed in Brucella broth selectively supplemented with modified
Brucella selective supplement (MBSS, Oxoid Limited, Cambridge, UK) as
previously described
20. Plates were examined for the presence or absence of B.
melitensis.
Tissue burden was determined for samples of the lung, liver and spleen from all
animals in the low dose aerosol study (Groups 1–5) and from half of the animals
in each group from the pathophysiology study (Groups 6–21), as previously
described
20. Complete necropsies were performed on all mice in the patho-
physiology study, but histopathology was only performed on the mice that were
not assessed for tissue burden. The heart, lungs, liver, spleen, kidneys, brain,
ovaries or testes as appropriate, and mediastinal lymph nodes were fixed in
formalin, processed for routine hematoxylin and eosin paraffin sections and
examined microscopically by a board-certified veterinary pathologist All micro-
scopic findings were graded semi-quantitatively according to the following scale,
with the associated numerical score used to calculate average severity grades for
each lesion by group. Minimal (grade 1) represented the least detectable lesion;
mild (grade 2) represented an easily discernable lesion; moderate (grade 3)
represented a change affecting a large area of the represented tissue; and marked
(grade 4) represented a lesion that approached maximal.
Statistical methods. Animal group randomizations were performed with SASH
statistical software Version 9.1.3 (SAS Institute, Cary, NC) utilizing the Plan
procedure. No statistical differences in gender were observed in these studies and
therefore gender is not discussed in the results.
Geometric means by day were generated for both aerosol concentration and
spray factor for each level of target nebulizer concentration, as well as overall.
Spray factors were calculated as aerosol concentration divided by targeted nebu-
lizer concentration. The aerosol characterization data were examined under a
number of potential statistical models to explain the relationship between aerosol
concentration and target nebulizer concentration, and the final model selected was
a regression model incorporating a random effect for test day. The model is the
following: log10 (yijk) 5 ai 1 b * log10(x j(i)) 1 eijk. i 5 3 test days; j(i) 5 4 levels
of target nebulizer concentration j within test day i; k 5 3 replicates per test
condition; log10 (yijk) 5 log10 transformed aerosol concentration for each of the k
replicates with the jth level of target nebulizer concentration for the ith day; ai 5
intercept of the aerosol concentration versus target nebulizer concentration rela-
tionship for the ith day, treated as a random effect assumed to be distributed as N
(a,s
2
a); b 5 common slope of the aerosol concentration versus nebulizer con-
centration relationship treated as a fixed effect; x j(i) 5 known log10 transformed
target nebulizer concentration values for the jth level; eijk 5 residual error left
unexplained by the model, random effect assumed to be distributed as N (0, s
2)
and independent of the ai. The model was fitted in SASH (version 9.1) using
PROC MIXED.
For aerosol-challenged animals in the pathophysiology study, a Fisher’s exact test
wasusedtocomparetheproportionofanimalsthatwerebacteremicbygroupateach
scheduled euthanasia time point. For animals challenged by the IN route, Dunnett’s
multiple comparison procedure was used to compare the proportion of animals that
were bacteremic in each group to the proportion of animals that were bacteremic in
the control group. The spleen weights for each aerosol challenge group and IN
challenge group of mice euthanized on days 14, 28, 42 and 56 post-challenge were
compared to the control group by the T-test. Bacterial burdens in the lung, liver and
spleen for each aerosol challenge group and the IN group were compared to the
control group by T-test on ranks.
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